VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MMSI
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
MMSIMerit Medical Systems, Inc.
$70.09$4.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksMMSIFinancials

Merit Medical Systems, Inc. (MMSI) Financials

30Y historyFree accessUpdated daily

Revenue growth remains stable, yet operating margins struggle to scale beyond the 14% ceiling observed in 2025Q1 due to persistent SG&A absorption.

MMSI Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue1.54B1.51B1.36B1.26B1.15B1.07B963.88M994.85M882.75M727.85M603.84M542.15M509.69M449.05M394.29M359.45M296.75M257.46M227.14M207.77M190.67M166.59M151.4M135.95M116.23M104.04M91.45M78M68.4M60.6M50.5M
Revenue Growth %11.17%11.66%7.89%9.24%7.09%11.5%-3.11%12.7%21.28%20.54%11.38%6.37%13.5%13.89%9.69%21.13%15.26%13.35%9.33%8.96%14.46%10.03%11.36%16.97%11.72%13.77%17.24%14.04%12.87%20%18.54%
Cost of Goods Sold791.29M777.79M713.18M673.49M631.88M589.42M562.7M562.49M487.98M401.6M338.81M306.37M284.47M254.68M212.3M193.98M168.26M148.66M133.87M127.98M117.6M97.49M83.91M75.23M67.71M65.94M56.5M44.3M39.6M35.1M26.9M
COGS % of Revenue-51.35%52.57%53.56%54.9%54.84%58.38%56.54%55.28%55.18%56.11%56.51%55.81%56.72%53.84%53.97%56.7%57.74%58.94%61.6%61.67%58.52%55.42%55.33%58.26%63.38%61.79%56.79%57.89%57.92%53.27%
Gross Profit750.98M736.94M643.33M583.87M519.1M485.33M401.18M432.37M394.77M326.25M265.02M235.78M225.22M194.37M181.99M165.47M128.5M108.8M93.27M79.79M73.08M69.09M67.49M60.72M48.52M38.1M34.94M33.7M28.8M25.5M23.6M
Gross Margin %48.69%48.65%47.43%46.44%45.1%45.16%41.62%43.46%44.72%44.82%43.89%43.49%44.19%43.28%46.16%46.03%43.3%42.26%41.06%38.4%38.33%41.48%44.58%44.67%41.74%36.62%38.21%43.21%42.11%42.08%46.73%
Gross Profit Growth %-14.55%10.18%12.48%6.96%20.98%-7.21%9.52%21%23.1%12.4%4.69%15.87%6.8%9.99%28.77%18.1%16.65%16.89%9.19%5.77%2.37%11.14%25.16%27.34%9.03%3.69%17.01%12.94%8.05%22.28%
Operating Expenses563.42M552.57M487.64M458.73M431.54M424.42M402.74M416.93M335.55M280.54M229.63M197.16M184.53M162.53M149.9M126.44M102.95M75.95M62.29M56.82M54.07M45.57M40.15M35.09M31.74M28.16M31.48M27.6M23.5M22.8M19.2M
OpEx % of Revenue-36.48%35.95%36.48%37.49%39.49%41.78%41.91%38.01%38.54%38.03%36.37%36.2%36.19%38.02%35.18%34.69%29.5%27.42%27.35%28.36%27.36%26.52%25.81%27.31%27.07%34.43%35.38%34.36%37.62%38.02%
Selling, General & Admin465.94M455.21M376.73M373.68M342.52M335.69M297.72M327.27M276.02M229.13M184.4M156.35M147.89M128.64M122.11M104.5M87.61M64.79M53.13M48.13M45.49M38.58M35.07M30.47M27.73M24.04M23.3M20.4M17.5M15.7M14.3M
SG&A % of Revenue-30.05%27.77%29.72%29.76%31.23%30.89%32.9%31.27%31.48%30.54%28.84%29.02%28.65%30.97%29.07%29.52%25.16%23.39%23.17%23.86%23.16%23.16%22.41%23.86%23.11%25.48%26.15%25.58%25.91%28.32%
Research & Development97.48M97.35M83.81M82.73M75.51M71.25M57.54M65.61M59.53M51.4M45.23M40.81M36.63M33.89M27.8M21.94M15.34M11.17M9.16M8.69M8.58M6.99M5.08M4.63M4.01M4.12M3.86M3.6M3.2M4.4M2.5M
R&D % of Revenue-6.43%6.18%6.58%6.56%6.63%5.97%6.6%6.74%7.06%7.49%7.53%7.19%7.55%7.05%6.1%5.17%4.34%4.03%4.18%4.5%4.2%3.35%3.4%3.45%3.96%4.23%4.62%4.68%7.26%4.95%
Other Operating Expenses0027.09M3.52M13.5M17.48M47.48M24.04M63K-872K-773K-386K18K-216K0000000000004.32M3.6M2.8M2.7M2.4M
Operating Income187.74M184.38M155.69M123.94M87.56M60.92M-1.56M15.43M58.62M33.07M34.88M37.54M40.17M27.84M29.64M33.19M17.2M32.85M30.98M22.97M19.01M23.52M27.34M25.63M16.78M9.94M3.46M6.1M5.3M2.7M4.4M
Operating Margin %12.17%12.17%11.48%9.86%7.61%5.67%-0.16%1.55%6.64%4.54%5.78%6.92%7.88%6.2%7.52%9.23%5.8%12.76%13.64%11.06%9.97%14.12%18.06%18.85%14.43%9.55%3.78%7.82%7.75%4.46%8.71%
Operating Income Growth %-18.42%25.62%41.55%43.74%3999.87%-110.12%-73.67%77.26%-5.18%-7.1%-6.53%44.25%-6.06%-10.69%92.92%-47.62%6.01%34.89%20.83%-19.18%-13.97%6.67%52.78%68.77%187.31%-43.29%15.09%96.3%-38.64%76%
EBITDA290.11M319.03M270.43M225.24M179.76M156.7M105.25M119.79M128.16M86.65M78.63M74.97M76.09M60.39M52.17M52.38M32.06M45.12M41.22M32.28M27.11M29.16M31.83M29.86M21.16M14.5M7.78M9.7M8.1M5.4M6.8M
EBITDA Margin %18.81%21.06%19.94%17.91%15.62%14.58%10.92%12.04%14.52%11.91%13.02%13.83%14.93%13.45%13.23%14.57%10.8%17.52%18.15%15.54%14.22%17.51%21.03%21.96%18.2%13.94%8.51%12.44%11.84%8.91%13.47%
EBITDA Growth %-0.24%17.97%20.06%25.3%14.72%48.88%-12.13%-6.53%47.91%10.2%4.89%-1.48%26.01%15.74%-0.4%63.39%-28.94%9.45%27.71%19.07%-7.04%-8.38%6.61%41.13%45.87%86.45%-19.8%19.75%50%-20.59%61.9%
D&A (Non-Cash Add-back)102.37M134.65M114.73M101.29M92.2M95.78M106.82M104.36M69.55M53.58M43.76M37.42M35.93M32.54M22.53M19.19M14.86M12.27M10.24M9.31M8.1M5.64M4.49M4.23M4.38M4.56M4.32M3.6M2.8M2.7M2.4M
EBIT143.58M184.38M159.24M127.6M88.97M59.18M-3.24M14.9M59.88M43.62M34.18M37.43M40.4M27.88M28.22M33.66M17.38M33.12M31.86M22.97M19.01M23.52M27.34M26.14M16.77M9.94M3.46M6.1M5.3M2.7M4.4M
Net Interest Income-8.61M-11.39M-4.99M-13.05M-5.9M-4.49M-9.39M-12.7M-9.16M-7.36M-8.72M-5.96M-8.61M-7.79M-378K-660K-562K150K764K000000000000
Interest Income15.18M15.07M26.23M2.46M439K769K604K01.2M381K81K272K217K255K226K129K34K178K781K000000000000
Interest Expense13.37M26.46M31.22M15.51M6.34M5.26M9.99M12.7M10.36M7.74M8.8M6.23M8.83M8.04M604K789K596K28K17K000000000000
Other Income/Expense-1.22M-13.44M-5.7M-11.86M-4.93M-7M-11.67M-13.24M-9.1M2.81M-9.49M-6.34M-8.59M-8.01M-2.02M-315K-416K247K861K429K174K379K666K885K-13K-151.23K-2.69M-1.4M-1.1M-1M-900K
Pretax Income186.53M170.94M149.99M112.09M82.63M53.92M-13.23M2.19M49.52M35.88M25.39M31.2M31.57M19.84M27.62M32.88M16.79M33.09M31.84M23.4M19.18M23.9M28.01M27.02M16.76M9.79M773.85K4.7M4.2M1.7M3.5M
Pretax Margin %12.09%11.29%11.06%8.91%7.18%5.02%-1.37%0.22%5.61%4.93%4.2%5.75%6.19%4.42%7%9.15%5.66%12.85%14.02%11.26%10.06%14.35%18.5%19.88%14.42%9.41%0.85%6.03%6.14%2.81%6.93%
Income Tax47.19M42.45M29.64M17.68M8.11M5.46M-3.39M-3.26M7.5M8.36M5.26M7.4M8.6M3.27M7.91M9.83M4.33M10.56M11.12M7.81M6.88M8.12M10.07M9.73M5.45M3.05M-52.71K1.5M1.7M900K1.3M
Effective Tax Rate %25.3%24.83%19.76%15.77%9.82%10.13%25.61%-148.56%15.15%23.29%20.74%23.71%27.23%16.48%28.63%29.9%25.78%31.92%34.91%33.38%35.88%33.98%35.97%36%32.53%31.18%-6.81%31.91%40.48%52.94%37.14%
Net Income139.34M128.49M120.36M94.41M74.52M48.45M-9.84M5.45M42.02M27.52M20.12M23.8M22.97M16.57M19.71M23.04M12.46M22.53M20.73M15.59M12.3M15.78M17.93M17.3M11.31M6.74M826.56K3.2M2.5M800K2.2M
Net Margin %9.03%8.48%8.87%7.51%6.47%4.51%-1.02%0.55%4.76%3.78%3.33%4.39%4.51%3.69%5%6.41%4.2%8.75%9.13%7.5%6.45%9.47%11.84%12.72%9.73%6.47%0.9%4.1%3.65%1.32%4.36%
Net Income Growth %13.96%6.76%27.48%26.7%53.79%592.27%-280.57%-87.03%52.66%36.79%-15.47%3.6%38.65%-15.93%-14.47%84.94%-44.7%8.7%32.97%26.72%-22.04%-12.01%3.68%52.92%67.9%714.94%-74.17%28%212.5%-63.64%83.33%
Net Income (Continuing)139.34M128.49M120.36M94.41M74.52M48.45M-9.84M5.45M42.02M27.52M20.12M23.8M22.97M16.57M19.71M23.04M12.46M22.53M20.73M15.59M12.3M15.78M17.93M17.3M11.31M6.74M826.56K3.2M2.5M800K2.2M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000500K400K400K
EPS (Diluted)2.322.132.031.621.290.84-0.180.100.780.550.450.530.530.390.460.580.340.630.580.440.350.460.520.510.340.230.030.120.100.030.09
EPS Growth %13.24%4.93%25.31%25.58%53.57%566.67%-285.76%-87.58%41.82%22.22%-15.09%0%35.9%-15.22%-20.69%70.59%-46.03%8.62%31.82%25.71%-23.91%-11.54%1.96%50%47.83%698.61%-76%26.32%199.68%-64.5%72.39%
EPS (Basic)-2.172.071.641.310.86-0.180.100.800.560.450.540.530.390.470.590.350.640.600.460.360.470.540.530.370.240.030.120.100.030.09
Diluted Shares Outstanding60.01M60.46M59.37M58.36M57.67M57.36M55.43M56.23M53.93M50.1M44.86M44.51M43.41M42.88M42.61M39.73M35.98M35.76M35.69M35.26M35.31M34.81M34.61M33.79M32.8M29.84M27.29M26.27M26M25.25M24.59M
Basic Shares Outstanding59.51M59.16M58.22M57.59M56.81M56.15M55.43M55.08M52.27M48.8M44.41M44.04M43.14M42.61M42.18M39.09M35.29M35.01M34.71M34.28M34.17M33.56M32.88M31.56M30.11M28.17M26.84M26.18M25.76M25.25M24.48M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeStable
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Operational margin scaling challenges

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Consistent Revenue Growth Amidst Volatility

According to recent quarterly filings, Merit Medical has maintained a steady revenue growth trajectory, with year-over-year figures consistently hovering between 5.6% and 13.1% over the last ten quarters, suggesting that the company's procedural accessory model provides a durable, non-elective demand base despite broader macroeconomic fluctuations.

The company's ability to sustain mid-to-high single-digit growth indicates that its 'breadth-of-bag' strategy effectively captures procedural volume in cath labs. However, the variability in quarterly growth rates suggests that revenue may be sensitive to the timing of large distributor orders and the successful integration of tuck-in acquisitions.

Structural Gross Margin Ceiling Constraints

Based on reported financial statements, Merit Medical's gross margins have largely remained range-bound between 46% and 49%, reflecting a product mix heavily weighted toward high-volume, lower-cost disposables rather than the premium-priced therapeutic implants that typically command margins exceeding 60% in the broader medical device sector.

This margin profile suggests that the company faces structural limitations in pricing power, likely due to the commoditized nature of many of its accessory components. Investors should monitor whether the 'Foundations for Growth' initiative can drive meaningful expansion through manufacturing automation or if the current margin ceiling is a permanent feature of their business model.

Operating Leverage Remains Elusive Target

As indicated by the provided income statement data, operating income has struggled to scale proportionally with gross profit, with operating margins fluctuating between 10% and 14% over the last ten quarters, implying that SG&A expenses continue to absorb a significant portion of incremental gross profit gains.

The lack of consistent operating leverage suggests that the company's frequent acquisition strategy may be creating ongoing integration costs that offset efficiency gains. Without a clear trend of SG&A as a percentage of revenue declining, the company may continue to face difficulty in expanding its bottom-line profitability.

Stock-Based Compensation Impacts Earnings Quality

Analysis of recent SEC filings reveals that stock-based compensation has trended upward, reaching $13.6M in 2025Q3, which warrants further investigation into how these non-cash expenses influence the quality of reported net income and the underlying economic reality of the company's earnings per share growth.

The divergence between net income growth and EPS performance in certain periods suggests that investors should be cautious of relying solely on GAAP figures. The persistent use of equity-based incentives may be masking the true cost of talent retention and acquisition integration, potentially overstating the company's operational efficiency.

Risks of Margin Compression Persist

Based on the reported figures, short-term margin volatility remains a primary concern, as evidenced by the dip to 41.8% gross margin in 2023Q4, which highlights the company's vulnerability to input cost spikes and the potential for GPO pricing pressure to erode profitability in the future.

While the company's defensive product profile is a strength, the reliance on high-volume disposables leaves it exposed to hospital cost-containment efforts. If hospital procurement departments successfully consolidate vendors further, Merit Medical may find it difficult to maintain its current margin levels without sacrificing market share.

MMSI — Frequently Asked Questions

Quick answers to the most common questions about buying MMSI stock.

What was Merit Medical Systems, Inc.'s (MMSI) revenue in 2025?

For fiscal year 2025, Merit Medical Systems, Inc. (MMSI) reported total revenue of $1.51B. This represents a 2899.5% increase compared to $50.5M in 1996.

Is Merit Medical Systems, Inc. (MMSI) profitable?

Merit Medical Systems, Inc. (MMSI) is profitable, generating $128.5M in net income for the fiscal year ending 2025 with a net profit margin of 8.5%.

What is Merit Medical Systems, Inc.'s operating profit margin?

Merit Medical Systems, Inc. (MMSI) reported an operating income of $184.4M, resulting in an operating profit margin of 12.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Merit Medical Systems, Inc.'s gross profit and gross margin?

Merit Medical Systems, Inc. (MMSI) generated $736.9M in gross profit for the year, representing a gross profit margin of 48.7%. This demonstrates the company's core pricing power and production efficiency.